Live tape.Join the lounge

Research with context.

A clearer way to explore the market.

Create an account Contact the team

Market signals, research, watchlists, and alerts in one workspace.

Follow the signal.

Product Pricing FAQ

Data coverage Methodology Disclosures Contact

© 2026 Longbrunch. All rights reserved.

longbrunch/

ABUS/Research

Fundamentals

ARBUTUS BIOPHARMA CORP · Equity

Partial coverage

TradeShort termMedium termLong term

Financial health Growth Valuation Profitability Shareholder return

Financial health

2 current metrics

Total Assets2026-03-31: $277.16M
Total Liabilities2026-03-31: $16.99M

Historical trendData pending

Growth

4 current metrics

Eps2026-07-31: 0.83
Free Cash Flow2026-07-31: $-90.41M
Net Income2026-03-31: $169.7M
Revenue2026-03-31: $179.13M

Historical trendData pending

Valuation

3 current metrics

Market Cap2026-07-31: $857.31M
Trailing Pe2026-07-31: 5.228916
Trailing P/E: 5.23

Historical trendData pending

Profitability

2 current metrics

Ebitda2026-07-31: $155.14M
Operating Income2026-03-31: $169.12M

Historical trendData pending

Shareholder return

3 current metrics

Payout Ratio2026-07-31: 0%
Trailing Annual Dividend Rate2026-07-31: 0.0
Trailing Annual Dividend Yield2026-07-31: 0%

Historical trendData pending

Financial evidence

Statement-level periods and line items live in the dedicated view.

Open Financial Statements →